Quick Summary
Certican 0.75mg Tablet
Last updated on 31 Mar 2026 | 09:31 AM (IST)
₹2499
MRP: ₹2876
(You Save ₹377)
10 TABLET(s) IN A STRIP
13% OFF
₹2499
MRP: ₹2,876.00
Inclusive of all taxes
13% Off
Dispatch: Today
Care delivered without the wait. Your order is prioritized for rapid dispatch to ensure it reaches your doorstep on time.
Introduction
Certican 0.75mg Tablet is an antineoplastic and immunosuppressive medicine that contains Everolimus as its active ingredient. It belongs to the class of mTOR kinase inhibitors, which work by blocking specific proteins that help cancer cells grow and multiply. The Certican 0.75mg tablet composition allows it to be used in several medical conditions such as advanced breast cancer, renal cell carcinoma, pancreatic neuroendocrine tumors, and subependymal giant cell astrocytoma.
In organ transplantation, this medicine plays a vital role in preventing the body from rejecting a transplanted kidney. Doctors commonly prescribe it as Certican 0.75mg for kidney transplant patients. The Certican 0.75mg dosage for kidney transplant is carefully decided based on the patient’s weight, immune response, and other medications being used. Regular monitoring of blood levels helps doctors adjust the dose for safe and effective therapy.
In oncology, Certican 0.75mg for breast cancer is used to treat patients with advanced hormone receptor-positive disease, especially those who no longer respond to other treatments. It works by slowing tumor cell growth and cutting off the blood supply that tumors need to survive. When taken as prescribed, it helps improve disease control and overall quality of life.
For patients comparing options, checking the Certican 0.75mg price in India can help plan long-term treatment costs. The price may vary depending on brand, pharmacy, and location. To make treatment more convenient, patients can also buy Certican 0.75mg online in India from licensed pharmacy websites with a valid prescription. Purchasing online ensures authenticity and timely delivery from verified distributors.
If the medicine is unavailable or if cost is a concern, your doctor may suggest a Certican 0.75mg substitute India that contains the same active ingredient, Everolimus. Any substitution should be done only under medical supervision to ensure similar safety and efficacy.
Overall, Certican 0.75mg Tablet is an important treatment option for both cancer and transplant patients. Its ability to regulate cell growth and control immune response makes it a trusted choice among healthcare professionals. Patients should take the medicine exactly as prescribed, avoid self-adjusting the dose, and attend regular follow-ups for the best treatment outcomes.
Uses
Certican 0.75mg Tablet uses
- Advanced breast cancer
- Advanced renal cell carcinoma
- Advanced pancreatic neuroendocrine tumours
- Treatment of subependymal giant cell astrocytoma
How Certican 0.75mg Tablet works
Certican 0.75mg tablet inhibits the activity of a protein called mammalian target of rapamycin (mTOR), which regulates cell growth. This drug can slow the growth of abnormal cancer cells by blocking the mTOR protein and helps to reduce the size of tumours and improve outcomes in patients.
Interaction of Certican 0.75mg Tablet with other drugs
Inform your healthcare provider about all the medicines you take, including prescription medications, over-the-counter medications, nutritional or vitamin supplements, and herbal products. Certain medications may interact with Certican 0.75mg tablet and reduce effectiveness by causing undesirable side effects.
Storage conditions
- Store Certican 0.75mg tablet in the original package at room temperature (20°C to 25°C).
- Keep it out of reach from children.
How to take Certican 0.75mg Tablet
Take the Evermil 5mg tablet as advised by your physician. Do not crush, chew, or open the medicine. Your physician will decide the correct dosage and duration based on age, body weight, and disease condition. Only stop taking the tablet if your doctor advises you to stop.
Safety Advice for Certican 0.75mg Tablet
Breast Feeding
Certican 0.75mg tablet passes into your breast milk and harms your baby. It is unsafe to consume this tablet.
Alcohol
Consuming alcohol may affect the effectiveness of Certican 0.75mg tablet. Stop consuming alcohol if you are taking this medicine.
Liver
Inform your doctor if you have any liver problems before taking Certican 0.75mg tablet. Regular monitoring of liver function tests is recommended.
Lungs
It is not known whether Certican 0.75mg tablet can be used for patients with lung problems. Consult your doctor if you have any lung diseases before starting the treatment.
Driving
It is unsafe to drive vehicles or operate heavy machinery after taking Certican 0.75mg tablet, it may cause dizziness and impair your concentration.
Pregnancy
Certican 0.75mg tablet is not recommended for pregnant women as it may cause fetal harm. Consult your doctor if you are pregnant or planning for pregnancy during the treatment.
Side Effects
Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them. Certican 0.75mg side effects are
Serious
- Difficulty breathing, or swallowing
- Swelling of face, lips, tongue, throat
- Severe itching, red rash, raised bumps
Common
- Infection (chills, increased temperature)
- Coughing
- Wheezing
- Excessive thirst
- High urine output or severely decreased urine output
- Tiredness
- Bleeding
- Increased appetite with weight loss
Expert Tips
- Risk to unborn fetus: Certican 0.75mg tablet may cause harm to an unborn baby.
-
Inform your doctor if pregnant: Tell your healthcare provider if you are pregnant or planning to become pregnant before starting this treatment.
-
Pregnancy test required: Your doctor will conduct a pregnancy test before initiating treatment.
-
Use effective contraception: Discuss birth control methods with your healthcare provider and use them during treatment and for 8 weeks after your last dose.
-
Not recommended during breastfeeding: This medicine passes into breast milk, so breastfeeding is not advised during treatment.
-
Mouth ulcers or sores: Mouth ulcers or sores are common; your doctor will prescribe a mouthwash to help prevent and manage these symptoms.
-
Follow mouthwash instructions: Use the prescribed mouthwash as directed by your healthcare provider.
FAQs about Certican 0.75mg Tablet
Q1.
What you should know before taking Certican 0.75mg tablet?
Before taking Certican 0.75mg tablet, it is important to know that your risk of getting bacterial or viral infection increases with this treatment. If you have been infected with Hepatitis B, this drug increases the chances of reinfection. Tell your healthcare provider if you experience fever, chills, cough, yellowing of the skin, joint pain, or swelling during this treatment.
Q2.
Is it safe to use Certican 0.75mg tablet during pregnancy?
Certican 0.75mg tablet have the tendency to cause harm to the unborn fetus. Inform your healthcare provider before starting this treatment if you are pregnant, or planning for pregnancy. Your healthcare provider will conduct a pregnancy test before you start treatment with this drug.
Q3.
What are the side effects of Certican 0.75mg Tablet?
The common side effects that are likely to occur while you are on the treatment with Certican 0.75mg tablet are fever, chills, skin rash, joint pain, swelling, tiredness, loss of appetite, high risk of infection, mouth ulcers, and difficulty breathing.
Q4.
Is it safe to undergo surgery while on treatment with Certican 0.75mg tablet?
Certican 0.75mg tablet may lead to poor wound healing ability. Consult your healthcare provider and stop taking this tablet at least one week before planned surgery.
Q5.
Can I drink alcohol while taking Certican 0.75mg tablet?
It is generally recommended to avoid drinking alcohol while taking Certican 0.75mg tablet, as alcohol can increase the risk of liver damage.
Fact Box of Certican 0.75mg Tablet
|
Molecule name |
Everolimus |
|
Therapeutic class |
Antineoplastics |
|
Pharmacological class |
mTOR kinase inhibitors |
|
Indications |
1. Advanced breast cancer 2. Advanced renal cell carcinoma 3. Advanced pancreatic neuroendocrine tumors 4. Treatment of subependymal giant cell astrocytoma |
References
- Novartis Pharmaceuticals UK Limited, Electronic medicines compendium (EMC), [ Revised on June 2022] [ Accessed on 18th March 2023], https://www.medicines.org.uk/emc/files/pil.6658.pdf
- Jan Hasskarl; Everolimus; Recent Results in Cancer Research; Published on 2018; Accessed on 18/03/2023; https://pubmed.ncbi.nlm.nih.gov/30069763/
- Novartis Pharmaceuticals Corporation, US Food and Drug Administration, [ Revised on July 2012] [ Accessed on 18th March 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022334s016lbl.pdf
- Goodman & Gilman’s, The Pharmacological Basis of Therapeutics, Targeted therapy: tyrosine kinase inhibitors, monoclonal antibodies, and cytokines, 12th edition, 2011, 1743.
- KD Tripathi, Essentials of Medical Pharmacology, Immunosuppressant drugs, 7th edition, 2013, 878 - 882.
Disclaimer
MrMed’s primary intention is to ensure that its consumers get information that is reviewed by experts, accurate and trustworthy. The information and contents of this website are for informational purposes only. They are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of your doctor and discuss all your queries related to any disease or medicine. Do not disregard professional medical advice or delay in seeking it because of something you have read on MrMed. Our mission is to support, not replace, the doctor-patient relationship.
Did you find this information helpful?
Author Details
Written By
Dr. B. Deiva
Pharm D
Reviewed By
Dr. Tejashwin Adiga
MBBS
Last updated : 31 Mar 2026 | 09:31 AM (IST)
Want to know more?
Read Our Editorial Policy
